Newland Pharmaceutical (301277.SZ): Moxifloxacin hydrochloride API obtains CEP certificate

Newland Pharmaceutical (301277.SZ) announced that recently, the company received the Certificate of Suitability of the European Pharmacopoeia (CEP certificate) for moxifloxacin hydrochloride API issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Moxifloxacin hydrochloride is a quinolone antibiotic used to treat infectious diseases caused by pathogens susceptible to this product, such as bacterial sinusitis, acute exacerbation of bacterial chronic bronchitis, community-acquired pneumonia, uncomplicated skin and skin structure infections, complicated intra-abdominal infections, complicated skin and skin structure infections, etc. The company's obtaining of the CEP certificate for moxifloxacin hydrochloride API this time indicates the recognition and affirmation of the quality of this API by the regulated European market, marking that this API can be sold in the European market and other regulated markets that recognize the CEP certificate, bringing a positive impact on the company's further enrichment of products and expansion of the international market.